SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Gan & Lee’s GRADUAL-3 Study Meets Primary Endpoint for Weight Maintenance

Gan & Lee Pharmaceuticals said its GRADUAL-3 study of once-monthly bofanglutide maintenance therapy met its primary endpoint in weight control and maintenance over 24 weeks.

Related stories